MAP2K7 and lung carcinoma: The results of this study suggest that combined use of EGFR-TKI and MET inhibitors or inhibition of downstream signaling molecules, such as PI3K or MEK, might be a better second or third-line strategy for a group of patients with advanced lung cancer harboring wild-type EGFR.